HC Wainwright Predicts Lower Earnings for ProQR Therapeutics

ProQR Therapeutics N.V. (NASDAQ:PRQR) – Investment analysts at HC Wainwright cut their FY2028 earnings estimates for shares of ProQR Therapeutics in a research report issued on Thursday, October 1st. HC Wainwright analyst A. Ghosh now forecasts that the biopharmaceutical company will post earnings per share of ($0.37) for the year, down from their previous forecast of ($0.27). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for ProQR Therapeutics’ FY2029 earnings at ($0.32) EPS and FY2030 earnings at ($0.18) EPS.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.04. The company had revenue of $10.00 million during the quarter, compared to analysts’ expectations of $4.56 million. ProQR Therapeutics had a negative net margin of 223.51% and a negative return on equity of 73.83%.

PRQR has been the topic of a number of other research reports. Wall Street Zen raised ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings upgraded ProQR Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. JonesTrading reduced their price objective on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, June 26th. Citigroup restated a “market outperform” rating on shares of ProQR Therapeutics in a research note on Thursday. Finally, Bank of America began coverage on shares of ProQR Therapeutics in a research report on Thursday, August 20th. They set a “buy” rating and a $8.00 target price on the stock. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.60.

ProQR Therapeutics Stock Performance

NASDAQ PRQR opened at $1.67 on Monday. ProQR Therapeutics has a twelve month low of $1.33 and a twelve month high of $3.10. The stock has a market capitalization of $175.95 million, a PE ratio of -3.63 and a beta of 0.20. The stock has a 50-day simple moving average of $1.94 and a 200 day simple moving average of $1.76.

Insider Activity

In other ProQR Therapeutics news, Director Bart Filius purchased 150,000 shares of the company’s stock in a transaction that occurred on Friday, July 17th. The stock was purchased at an average price of $1.72 per share, with a total value of $258,000.00. Following the completion of the transaction, the director directly owned 300,000 shares of the company’s stock, valued at approximately $516,000. This trade represents a 100.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Daniel de Boer purchased 150,000 shares of the business’s stock in a transaction on Thursday, July 9th. The shares were acquired at an average price of $1.74 per share, with a total value of $261,000.00. Following the purchase, the chief executive officer owned 300,000 shares of the company’s stock, valued at approximately $522,000. This trade represents a 100.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 8.40% of the company’s stock.

Institutional Trading of ProQR Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Walleye Capital LLC grew its position in ProQR Therapeutics by 2.7% in the first quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company’s stock valued at $984,000 after acquiring an additional 15,744 shares during the period. Bank of America Corp DE lifted its holdings in shares of ProQR Therapeutics by 6.4% during the first quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock valued at $300,000 after acquiring an additional 11,186 shares during the period. RFG Advisory LLC boosted its stake in shares of ProQR Therapeutics by 236.8% in the 2nd quarter. RFG Advisory LLC now owns 64,000 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 45,000 shares in the last quarter. Finally, Axiom Investment Management LLC acquired a new stake in shares of ProQR Therapeutics in the 1st quarter valued at $53,000. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA-based medicines for genetic diseases. The company’s research is centered on using RNA therapies to correct or modify disease-causing genetic information, with the goal of addressing conditions that may not be effectively treated through conventional drug-development approaches.

ProQR’s technology portfolio includes Axiomer, an RNA-editing platform designed to make precise changes to RNA inside cells. The company has also developed investigational therapies for inherited retinal diseases and other genetic disorders.